Hui Zhang1, Baowei Li1, Hebao Zhao1, Jin Chang2. 1. Department of Radiology, The Affiliated Hospital of Hebei Engineering University Handan 056006, China. 2. Department of Aesthetic Surgery, The Affiliated Hospital of Hebei Engineering University Handan 056006, China.
Abstract
OBJECTIVE: Our study aims to measure the expression level of serum microRNA-205 (miRNA-205, miR-205) in breast cancer, and evaluate the diagnostic value of miR-205 as a noninvasive biomarker for the early detection of breast cancer and other human cancers through a meta-analysis. METHODS: In the first phase, an experiment based on 58 breast cancer patients and 93 healthy controls was carried out to figure out the diagnostic performance of serum miR-205 for breast cancer. The study was conducted by using Reverse Transcription and quantitative Real-time polymerase Cycle Reaction (RT-qPCR). In the second phase, a meta-analysis was performed to evaluate the diagnostic value of miR-205 for various cancers. RESULTS: The test showed that the normalized expression levels of miR-205 in serum were evidently higher in healthy control than in breast cancer with a sensitivity and specificity at the optimal cutoff of 86.2% and 82.8%, respectively. The meta-analysis received a sensitivity of 75% and a specificity of 84%, and an AUC of 0.87. CONCLUSION: Our study determined that as a noninvasive and accessible biomarker, miR-205 not only has high clinical diagnostic value in the detection of breast cancer, but also plays an important role in clinical utilization of diagnosing various cancers. Further researches based on larger-scale subjects and additional improvement should be carried out to confirm our results.
OBJECTIVE: Our study aims to measure the expression level of serum microRNA-205 (miRNA-205, miR-205) in breast cancer, and evaluate the diagnostic value of miR-205 as a noninvasive biomarker for the early detection of breast cancer and other humancancers through a meta-analysis. METHODS: In the first phase, an experiment based on 58 breast cancerpatients and 93 healthy controls was carried out to figure out the diagnostic performance of serum miR-205 for breast cancer. The study was conducted by using Reverse Transcription and quantitative Real-time polymerase Cycle Reaction (RT-qPCR). In the second phase, a meta-analysis was performed to evaluate the diagnostic value of miR-205 for various cancers. RESULTS: The test showed that the normalized expression levels of miR-205 in serum were evidently higher in healthy control than in breast cancer with a sensitivity and specificity at the optimal cutoff of 86.2% and 82.8%, respectively. The meta-analysis received a sensitivity of 75% and a specificity of 84%, and an AUC of 0.87. CONCLUSION: Our study determined that as a noninvasive and accessible biomarker, miR-205 not only has high clinical diagnostic value in the detection of breast cancer, but also plays an important role in clinical utilization of diagnosing various cancers. Further researches based on larger-scale subjects and additional improvement should be carried out to confirm our results.
Entities:
Keywords:
breast cancer; diagnostic value; meta-analysis; miR-205; serum; various cancers
Authors: Erno Wienholds; Wigard P Kloosterman; Eric Miska; Ezequiel Alvarez-Saavedra; Eugene Berezikov; Ewart de Bruijn; H Robert Horvitz; Sakari Kauppinen; Ronald H A Plasterk Journal: Science Date: 2005-05-26 Impact factor: 47.728
Authors: Pablo Landgraf; Mirabela Rusu; Robert Sheridan; Alain Sewer; Nicola Iovino; Alexei Aravin; Sébastien Pfeffer; Amanda Rice; Alice O Kamphorst; Markus Landthaler; Carolina Lin; Nicholas D Socci; Leandro Hermida; Valerio Fulci; Sabina Chiaretti; Robin Foà; Julia Schliwka; Uta Fuchs; Astrid Novosel; Roman-Ulrich Müller; Bernhard Schermer; Ute Bissels; Jason Inman; Quang Phan; Minchen Chien; David B Weir; Ruchi Choksi; Gabriella De Vita; Daniela Frezzetti; Hans-Ingo Trompeter; Veit Hornung; Grace Teng; Gunther Hartmann; Miklos Palkovits; Roberto Di Lauro; Peter Wernet; Giuseppe Macino; Charles E Rogler; James W Nagle; Jingyue Ju; F Nina Papavasiliou; Thomas Benzing; Peter Lichter; Wayne Tam; Michael J Brownstein; Andreas Bosio; Arndt Borkhardt; James J Russo; Chris Sander; Mihaela Zavolan; Thomas Tuschl Journal: Cell Date: 2007-06-29 Impact factor: 41.582
Authors: John Le Quesne; Julia Jones; Joanna Warren; Sarah-Jane Dawson; H Raza Ali; Helen Bardwell; Fiona Blows; Paul Pharoah; Carlos Caldas Journal: J Pathol Date: 2012-05-08 Impact factor: 7.996
Authors: Enders K O Ng; Rufina Li; Vivian Y Shin; Hong Chuan Jin; Candy P H Leung; Edmond S K Ma; Roberta Pang; Daniel Chua; Kent-Man Chu; W L Law; Simon Y K Law; Ronnie T P Poon; Ava Kwong Journal: PLoS One Date: 2013-01-03 Impact factor: 3.240
Authors: Stephen Taplin; Linn Abraham; William E Barlow; Joshua J Fenton; Eric A Berns; Patricia A Carney; Gary R Cutter; Edward A Sickles; D'Orsi Carl; Joann G Elmore Journal: J Natl Cancer Inst Date: 2008-06-10 Impact factor: 13.506
Authors: Alberto Izzotti; Stefano Carozzo; Alessandra Pulliero; Dinara Zhabayeva; Jean Louis Ravetti; Rakhmet Bersimbaev Journal: Am J Cancer Res Date: 2016-07-01 Impact factor: 6.166